Charles Schwab’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $238M | Buy |
1,222,473
+87,174
| +8% | +$18.1M | 0.03% | 405 |
|
|
2026
Q1 | $255M | Buy |
1,135,299
+31,840
| +3% | +$7.93M | 0.04% | 354 |
|
|
2025
Q4 | $266M | Buy |
1,103,459
+35,816
| +3% | +$9.16M | 0.04% | 344 |
|
|
2025
Q3 | $292M | Buy |
1,067,643
+46,642
| +5% | +$12.7M | 0.05% | 324 |
|
|
2025
Q2 | $263M | Buy |
1,021,001
+22,873
| +2% | +$5.46M | 0.05% | 324 |
|
|
2025
Q1 | $223M | Buy |
998,128
+41,108
| +4% | +$9.6M | 0.04% | 353 |
|
|
2024
Q4 | $219M | Buy |
957,020
+32,973
| +4% | +$7.94M | 0.04% | 360 |
|
|
2024
Q3 | $226M | Buy |
924,047
+13,985
| +2% | +$3.12M | 0.04% | 339 |
|
|
2024
Q2 | $174M | Buy |
910,062
+11,915
| +1% | +$2.42M | 0.03% | 425 |
|
|
2024
Q1 | $178M | Buy |
898,147
+34,858
| +4% | +$6.39M | 0.04% | 384 |
|
|
2023
Q4 | $149M | Buy |
863,289
+46,113
| +6% | +$7.08M | 0.04% | 406 |
|
|
2023
Q3 | $121M | Buy |
817,176
+2,882
| +0.4% | +$521K | 0.03% | 435 |
|
|
2023
Q2 | $178M | Buy |
814,294
+11,716
| +1% | +$2.61M | 0.05% | 329 |
|
|
2023
Q1 | $176M | Buy |
802,578
+14,295
| +2% | +$3.1M | 0.05% | 321 |
|
|
2022
Q4 | $164M | Buy |
788,283
+13,038
| +2% | +$2.86M | 0.05% | 326 |
|
|
2022
Q3 | $169M | Buy |
775,245
+9,417
| +1% | +$2.14M | 0.06% | 289 |
|
|
2022
Q2 | $161M | Buy |
765,828
+11,470
| +2% | +$2.44M | 0.06% | 311 |
|
|
2022
Q1 | $183M | Buy |
754,358
+3,521
| +0.5% | +$852K | 0.06% | 314 |
|
|
2021
Q4 | $196M | Buy |
750,837
+14,247
| +2% | +$3.7M | 0.06% | 303 |
|
|
2021
Q3 | $194M | Sell |
736,590
-21,029
| -3% | -$5.75M | 0.06% | 278 |
|
|
2021
Q2 | $187M | Sell |
757,619
-7,697
| -1% | -$1.62M | 0.06% | 282 |
|
|
2021
Q1 | $148M | Buy |
765,316
+12,796
| +2% | +$2.57M | 0.05% | 318 |
|
|
2020
Q4 | $160M | Buy |
752,520
+33,779
| +5% | +$6.74M | 0.06% | 275 |
|
|
2020
Q3 | $123M | Buy |
718,741
+49,038
| +7% | +$9.06M | 0.06% | 299 |
|
|
2020
Q2 | $129M | Buy |
669,703
+29,833
| +5% | +$4.88M | 0.06% | 276 |
|
|
2020
Q1 | $94.2M | Buy |
639,870
+3,773
| +0.6% | +$601K | 0.06% | 299 |
|
|
2019
Q4 | $98.6M | Buy |
636,097
+13,373
| +2% | +$1.93M | 0.05% | 329 |
|
|
2019
Q3 | $84.1M | Buy |
622,724
+19,727
| +3% | +$2.58M | 0.05% | 354 |
|
|
2019
Q2 | $73.6M | Buy |
602,997
+15,341
| +3% | +$1.7M | 0.04% | 397 |
|
|
2019
Q1 | $61.1M | Sell |
587,656
-80,536
| -12% | -$8.31M | 0.04% | 446 |
|
|
2018
Q4 | $76.1M | Buy |
668,192
+4,455
| +0.7% | +$477K | 0.06% | 310 |
|
|
2018
Q3 | $76.6M | Sell |
663,737
-149,350
| -18% | -$16.4M | 0.05% | 349 |
|
|
2018
Q2 | $84.2M | Buy |
813,087
+87,893
| +12% | +$8.89M | 0.06% | 303 |
|
|
2018
Q1 | $71.4M | Buy |
725,194
+35,523
| +5% | +$3.36M | 0.06% | 328 |
|
|
2017
Q4 | $58.4M | Buy |
689,671
+28,691
| +4% | +$2.37M | 0.05% | 389 |
|
|
2017
Q3 | $50.9M | Buy |
660,980
+214,122
| +48% | +$16.4M | 0.04% | 409 |
|
|
2017
Q2 | $34.8M | Buy |
446,858
+5,339
| +1% | +$382K | 0.03% | 525 |
|
|
2017
Q1 | $31.8M | Buy |
441,519
+28,207
| +7% | +$1.95M | 0.03% | 556 |
|
|
2016
Q4 | $25.6M | Sell |
413,312
-90,984
| -18% | -$5.57M | 0.03% | 600 |
|
|
2016
Q3 | $32.6M | Buy |
504,296
+14,331
| +3% | +$954K | 0.04% | 480 |
|
|
2016
Q2 | $31.1M | Buy |
489,965
+78,692
| +19% | +$4.64M | 0.04% | 469 |
|
|
2016
Q1 | $23.8M | Buy |
411,273
+89,561
| +28% | +$5.07M | 0.03% | 539 |
|
|
2015
Q4 | $17.3M | Buy |
321,712
+18,149
| +6% | +$1.02M | 0.02% | 665 |
|
|
2015
Q3 | $15.5M | Buy |
303,563
+13,854
| +5% | +$746K | 0.02% | 683 |
|
|
2015
Q2 | $16.3M | Sell |
289,709
-25,900
| -8% | -$1.63M | 0.02% | 676 |
|
|
2015
Q1 | $22.7M | Buy |
315,609
+40,892
| +15% | +$2.66M | 0.03% | 508 |
|
|
2014
Q4 | $15.4M | Buy |
274,717
+13,299
| +5% | +$694K | 0.02% | 618 |
|
|
2014
Q3 | $12.9M | Buy |
261,418
+14,191
| +6% | +$723K | 0.02% | 656 |
|
|
2014
Q2 | $12.5M | Buy |
247,227
+15,406
| +7% | +$764K | 0.02% | 674 |
|
|
2014
Q1 | $10.4M | Buy |
231,821
+23,036
| +11% | +$1.03M | 0.02% | 779 |
|
|
2013
Q4 | $9.83M | Buy |
208,785
+22,549
| +12% | +$1.14M | 0.02% | 734 |
|
|
2013
Q3 | $9.95M | Buy |
186,236
+16,073
| +9% | +$780K | 0.02% | 640 |
|
|
2013
Q2 | $7.61M | Buy |
+170,163
| New | +$8.07M | 0.02% | 721 |
|
Other funds holding RMD
Charles Schwab's RMD Position: Q2 2026 in Review
Charles Schwab increased its ResMed (RMD) stake by 7.7% in Q2 2026, buying an estimated $18.1M and bringing the position to 1,222,473 shares worth $238M. The position accounts for 0.03% of the portfolio, ranked #405.
Charles Schwab first reported a position in RMD in Q2 2013 and has held it in 53 quarters since. The position peaked at $292M in Q3 2025. 882 funds tracked by Wall St. Rank hold RMD as of Q2 2026.
- Charles Schwab held 1,222,473 shares of ResMed worth $238M as of Q2 2026.
- Charles Schwab bought 87,174 ResMed shares in Q2 2026, an estimated $18.1M.
- ResMed made up 0.03% of Charles Schwab's portfolio in Q2 2026, its #405 holding.
- Charles Schwab first reported a position in ResMed in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's ResMed position peaked at $292M in Q3 2025.
- 882 funds tracked by Wall St. Rank held ResMed as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.